AzTrials
AzTrials

Stress Disorders, Post-TraumaticNCT06549049

A Transdiagnostic Sleep Health Intervention for Veterans With PTSD

A study testing TranS-C for PTSD in people with Stress Disorders, Post-Traumatic and Sleep Initiation and Maintenance Disorders, run by VA Office of Research and Development at 1 site in United States.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Sleep disturbance is a major problem in Veterans with posttraumatic stress disorder (PTSD). This study will test a version of a sleep treatment that's been shown to be effective in the general population, with some changes to tailor it to the needs of Veterans with PTSD and sleep disturbance. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
TranS-C for PTSD
Could I receive a placebo?
No, everyone receives an active treatment
How many people
182 participants
Where
1 siteUnited States
Study dates
1 Jan 2027to 31 Jan 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • U.S. Military Veteran engaged in VA primary and/or mental health care
  • Clinician-Administered post-traumatic stress disorder (PTSD) Scale (CAPS-5) PTSD diagnosis; or CAPS 5 score >=25 in the absence of full criteria
  • SCID Insomnia Disorder diagnosis, supported by Insomnia Severity Index (ISI) score >=10
  • CAPS-IV nightmare score >=4
  • Sleep-related functional impairment based on a World Health Organization Disability Assessment Schedule (WHODAS) score >=32
  • Willingness to engage in 8-12 sessions of treatment to address their sleep disturbance

Who cannot join

  • Current cognitive problems, active psychosis or mania, or other mental/cognitive conditions such as moderate to severe neurodegenerative disease that would render the participant unable to connect to videoconferencing platform, engage in remote psychotherapy, or communicate using the required VA secure email platform
  • No access to reliable internet service connected to a computer, iPad or similar device (telephone not adequate)
  • Inability or unwillingness to use a VA-approved videoconferencing platform and VA secure email
  • Current engagement in a sleep-focused psychotherapy, or plan to start a sleep-focused psychotherapy in the next 3 months. Sleep-focused psychotherapies include, but are not limited to, cognitive behavioral therapy for insomnia (CBT-I), brief behavioral treatment for insomnia (BBT-I), and imagery rehearsal therapy (IRT)

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site
  • San Francisco VA Medical Center, San Francisco, CA

    San Francisco, California, 94121-1563

    Emily J Berg, (415) 900-6016, emily.berg@va.gov

    Anne Richards, MD MPH

Other trials in United States

About this study

Official title: A Randomized, Controlled Trial of a Modified Sleep and Circadian Intervention for Veterans With PTSD: Advancing Psychosocial Rehabilitation Through Sleep Health

Sleep disturbance is a major problem in Veterans with posttraumatic stress disorder (PTSD). This study will test a version of a sleep treatment that's been shown to be effective in the general population, with some changes to tailor it to the needs of Veterans with PTSD and sleep disturbance.

Read the detailed description

Sleep disturbance in military Veterans with PTSD is a complex condition, typically characterized by insomnia and nightmares, and frequently accompanied by comorbid obstructive sleep apnea. Each of these problems are shown to influence the others, contributing to a complex sleep disturbance with profound impacts on daytime functioning and quality of life. A vicious cycle in which nighttime disturbances impact daytime functioning, and vice versa, often ensues. Addressing sleep disturbance in Veterans with PTSD therefore requires a multipronged approach that is tailored to each Veterans' constellation of symptoms and each Veterans' goals for sleep health. The Transdiagnostic sleep and circadian intervention (TranS-C), developed by sleep researchers Allison Harvey, Ph.D. and Daniel Buysse, M.D., involves a patient-centered, module-based, flexibly structured approach that tackles numerous sleep disturbances using evidence-based strategies with the overall goal of improving sleep and improving sleep-related impairments in daytime functioning. It is thus well-suited for tackling sleep disturbances and the associated impairments in social, occupational and overall functioning in Veterans with PTSD. The proposed study is a randomized, controlled clinical trial examining the effectiveness of a modified TranS-C intervention for Veterans with PTSD. The modified approach, referred to as TranS-C for PTSD (TSC-PTSD) elevates the importance of nightmare-focused, apnea-focused, and insomnia-focused modules relative to the standard intervention, incorporates an evidence-based relaxation module, and modifies the nightmare and apnea modules based on strategies used for Veterans in the VA healthcare system. The study will administer TSC-PTSD remotely to Veterans in their homes using a VA-approved video-conferencing platform. The study will recruit male and female U.S. military Veterans aged 18 and above throughout California and compare change in a comprehensive measure of daytime functioning and change in insomnia, nightmare and overall PTSD symptoms in participants randomized to the active intervention TSC-PTSD vs. participants randomized to a sleep psychoeducation control (SPC) intervention. The widely used and validated World Health Organization Disability Assessment Schedule (WHODAS) will serve as the primary outcome measure. The Insomnia Severity Index (ISI) and the Clinician-Administered PTSD Scale (CAPS) will be used to measure secondary outcomes. Eligible participants will have an insomnia diagnosis, a PTSD diagnosis (or moderate symptoms of PTSD in the absence of a full diagnosis), and clinically significant nightmares based on gold-standard clinician-administered interviews. All participants will complete baseline surveys related to daytime functioning and sleep-related symptoms prior to treatment initiation, and will complete these surveys again in week 5, and at the end of treatment. For additional high-resolution data on sleep patterns, all participants will record sleep-related information, including nightmare occurrence and severity, in the morning and at bedtime using a Veteran-tested and user-friendly sleep diary mobile app. Participants will also complete the clinical interview and self-report surveys at 3-month and 6-month follow-up, to assess the durability of treatment effects. The duration of TSC-PTSD may vary between a minimum of 8 and a maximum of 12 sessions and the psychoeducation control protocol will involve 10 sessions. The hypotheses are: 1) subjects randomized to TSC-PTSD will demonstrate greater improvement in WHODAS score relative to SPC from baseline to post-treatment; 2) subjects randomized to TSC-PTSD will demonstrate greater improvements in insomnia, nightmares and PTSD symptoms as demonstrated by improvements in the ISI, CAPS distressing dreams score, and CAPS total score relative to SPC from baseline to post-treatment; and 3) subjects randomized to TSC-PTSD will demonstrate greater sustained improvement in functional and clinical outcomes at 3-month and 6-month follow-up relative to SPC, and improvements in WHODAS score will be mediated by improvements in ISI, nightmares and TranS-C indicators of sleep health in both study groups. Findings in support of the investigators' hypotheses will provide a vital new tool for advancing rehabilitation in U.S. military Veterans with PTSD.

Being tested
TranS-C for PTSD, Sleep Psychoeducation Control
Keywords
Insomnia, Posttraumatic stress disorder, Veterans, Nightmares, Psychotherapy
Medical subject headings
Stress Disorders, Post-Traumatic, Sleep Initiation and Maintenance Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TranS-C for PTSDBehavioural

    Also called TSC-PTSD

    The Transdiagnostic sleep and circadian intervention (TranS-C), developed by Allison Harvey, Ph.D. and Daniel Buysse, M.D., involves a patient-centered, module-based, flexibly structured approach that tackles numerous sleep disturbances using evidence-based strategies with the goal of improving sleep and related impairments in daytime functioning. It is thus well-suited for tackling sleep disturbances and the associated impairments in social, occupational and overall functioning in Veterans with PTSD. The proposed study is a randomized, controlled clinical trial examining the effectiveness of a modified TranS-C intervention for Veterans with PTSD. The modified approach, TranS-C for PTSD (TSC-PTSD), elevates the importance of nightmare-focused, apnea-focused, and insomnia-focused modules relative to the standard intervention, incorporates an evidence-based relaxation module, and modifies the nightmare and apnea modules based on strategies used for Veterans in the VA healthcare system.

  • Sleep Psychoeducation ControlBehavioural

    Also called SPC

    Participants will receive psychoeducation about sleep.

Study groups in NCT06549049
Study groupRoleWhat they receive
Arm 1: ExperimentalExperimentalParticipants receiving experimental TSC-PTSD treatment.
Receives: Behavioral: TranS-C for PTSD
Arm 2: Active ControlActive comparatorParticipants receiving sleep psychoeducation control.
Receives: Behavioral: Sleep Psychoeducation Control

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. World Health Organization Disability Assessment Schedule (WHODAS)

    The WHODAS is a validated, comprehensive measure of health-related disability.

    Measured: Week 0, Week 5, Post-Treatment, 3-Month Follow-Up, 6-Month Follow-Up

Secondary outcomes (3)
  1. Insomnia Severity Index (ISI)

    The ISI will be used to measure change in severity of insomnia symptoms.

    Measured: Week 0, Week 5, Post-Treatment, 3-Month Follow-Up, 6-Month Follow-Up

  2. Clinician-Administered PTSD Scale for DSM-4 Distressing Dream Score (CAPS-4 Nightmare Item)

    The CAPS-IV Nightmare Item will be used to measure change in nightmare symptoms.

    Measured: Week 0, Week 5, Post-Treatment, 3-Month Follow-Up, 6-Month Follow-Up

  3. Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)

    The CAPS-5 will be used to measure change in overall PTSD symptoms.

    Measured: Week 0, Post-Treatment, 3-Month Follow-Up, 6-Month Follow-Up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Aug 2024
  2. Study start1 Jan 2027 (estimated)
  3. Primary completion31 Jan 2029 (estimated)
  4. Study completion31 Jan 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
The study involves a randomized, controlled, single-blind trial to evaluate the effectiveness of TranS-C modified for Veterans with PTSD (TSC-PTSD) in male and female Veterans who are enrolled in primary and/or mental health care in the VA system. Study treatment will be implemented remotely via live video visits using a VA-approved platform. Enrolled participants will be randomly assigned to the TSC-PTSD group or to the sleep psychoeducation control (SPC) group.
Masking
Single blind
Who is masked
Participant
Enrolment
182 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06549049
Sponsor's protocol ID
D4796-R
Other IDs
5I01RX004796-02
Status last verified
Nov 2026
First submitted
8 Aug 2024
Last updated
6 Nov 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing TranS-C for PTSD in people with Stress Disorders, Post-Traumatic and Sleep Initiation and Maintenance Disorders, run by VA Office of Research and Development at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Emily J Berg ((415) 900-6016, emily.berg@va.gov), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

World Health Organization Disability Assessment Schedule (WHODAS) (time frame: Week 0, Week 5, Post-Treatment, 3-Month Follow-Up, 6-Month Follow-Up). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in